Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of bladder cancer

Mo,Miao; Peng,Fenghua; Wang,Lu; Peng,Longkai; Lan,Gongbin; Yu,Shaojie

doi:10.3892/ol.2013.1419

Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of bladder cancer

Authors:
- Miao Mo
- Fenghua Peng
- Lu Wang
- Longkai Peng
- Gongbin Lan
- Shaojie Yu
View Affiliations

Affiliations: Department of Urologic Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China, Department of Otolaryngology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
Published online on: June 21, 2013 https://doi.org/10.3892/ol.2013.1419
Pages: 617-623

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial transcription factor A (TFAM) is required for mitochondrial DNA (mtDNA) replication and transcription. microRNAs (miRNAs) act as key factors in the regulation of gene expression. However, the roles of TFAM and certain miRNAs and their association in cancer development remain unclear. The present study reported that the expression of TFAM was significantly increased in bladder cancer, while the expression of miRNA‑590‑3p was downregulated. The luciferase assay showed that TFAM was the direct target of miRNA‑590‑3p. Furthermore, the forced overexpression of miRNA‑590‑3p significantly inhibited the proliferation, migration and colony‑forming ability of 5637 cells, which was in contrast with the results from the forced overexpression of TFAM in the 5637 cells. Furthermore, cell proliferation‑ and migration‑related genes, including phosphoinositide‑3‑kinase (PI3K), Akt, matrix metalloproteinase (MMP)‑2 and MMP9, were significantly downregulated in the miRNA‑590‑3p‑overexpressing 5637 cells, but upregulated in the TFAM‑overexpressing cells. In conclusion, the present study suggested that TFAM, a direct target of miRNA‑590‑3p, may play a significant role in the tumorigenesis of bladder cancer and thus may be a promising target for cancer therapeutics.

View Figures

View References

1.	Krynetskaia NF, Phadke MS, Jadhav SH and Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
3.	Ponisovskiy MR: Warburg effect mechanism as the target for theoretical substantiation of a new potential cancer treatment. Crit Rev Eukaryot Gene Expr. 21:13–28. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
5.	Toki N, Kagami S, Kurita T, et al: Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch. 456:387–393. 2010. View Article : Google Scholar
6.	Yoshida Y, Hasegawa J, Nezu R, et al: Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Sci. 102:578–582. 2011. View Article : Google Scholar
7.	Kurita T, Izumi H, Kagami S, et al: Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 103:239–444. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Tatarkova Z, Kuka S, Petráš M, et al: Why mitochondria are excellent targets for cancer therapy. Klin Onkol. 25:421–426. 2012.PubMed/NCBI
9.	Li X, Zhang G, Luo F, et al: Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep. 28:77–84. 2012.PubMed/NCBI
10.	He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature. 447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
12.	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Villa C, Fenoglio C, De Riz M, et al: Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. Rejuvenation Res. 14:275–281. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Vinuesa CG, Rigby RJ and Yu D: Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol. 28:112–138. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Hermeking H: MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Papaconstantinou IG, Lykoudis PM, Gazouli M, Manta A, Polymeneas G and Voros D: A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas. 41:671–677. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Majid S, Dar AA, Saini S, et al: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One. 7:e467432012. View Article : Google Scholar : PubMed/NCBI
18.	Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 5:402012. View Article : Google Scholar : PubMed/NCBI
19.	Vernochet C, Mourier A, Bezy O, et al: Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 16:765–776. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Uchiumi T and Kang D: The role of TFAM-associated proteins in mitochondrial RNA metabolism. Biochim Biophys Acta. 1820:565–570. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Wallace DC and Fan W: The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev. 23:1714–1736. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Han B, Izumi H, Yasuniwa Y, et al: Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem Biophys Res Commun. 408:45–51. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Guo J, Zheng L, Liu W, et al: Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res. 71:2978–2987. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Groblewska M, Siewko M, Mroczko B and Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar
25.	Rietz A and Spiers J: The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. Br J Pharmacol. 166:1225–1243. 2012. View Article : Google Scholar : PubMed/NCBI
26.	Mannello F and Medda V: Nuclear localization of matrix metal-loproteinases. Prog Histochem Cytochem. 47:27–58. 2012. View Article : Google Scholar
27.	Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 1825:29–36. 2012.PubMed/NCBI
28.	Siefert SA and Sarkar R: Matrix metalloproteinases in vascular physiology and disease. Vascular. 20:210–216. 2012. View Article : Google Scholar : PubMed/NCBI